Wire
IDEX Keeps Quarterly Dividend at $0.73 a Share, Payable July 24 to Shareholders of Record on July 6
IDEX Keeps Quarterly Dividend at $0.73 a Share, Payable July 24 to Shareholders of Record on July 6
$IEX
$IEX
15 stories mentioning IEXUpdated 13h ago
Every FINWIRES story that references IEX, newest first.
Insider Trading
Idex Insider Sold Shares Worth $3,311,195, According to a Recent SEC Filing
Eric D Ashleman, Director, CEO, and President, on May 11, 2026, sold 15,385 shares in Idex (IEX) for $3,311,195. Following the Form 4 filing with the SEC, Ashleman has control over a total of 66,658 common shares of the company, with 66,658 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/832101/000090514826002252/xslF345X05/form4.xml
$IEX
Wire
IDEX Raises Quarterly Dividend to $0.73 a Share From $0.71, Payable June 5 to Shareholders of Record on May 22
IDEX Raises Quarterly Dividend to $0.73 a Share From $0.71, Payable June 5 to Shareholders of Record on May 22
$IEX
Wire
Argus Adjusts Price Target on IDEX to $250 From $240
IDEX (IEX) has an average rating of overweight and mean price target of $236.46, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $214.86, Change: $-2.99, Percent Change: -1.37%
$IEX
Research
Research Alert: CFRA Reiterates Hold Opinion On Shares Of Iex
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We lift our 12-month target to $235 from $220 following Q1, valuing shares at 26x our 2027 EPS outlook of $9.04 (up from $8.99; 2026 EPS view revised to $8.50 from $8.28). IEX posted a robust Q1, with operating EPS of $2.00 rising 14% Y/Y and exceeding consensus by $0.23, propelled by standout performance in Health & Science Tech. Organic sales growth accelerated to 5% Y/Y from 1% in Q4, while orders hit a record $988M (up 10% Y/Y), signaling broadened demand. Health & Science Tech was the clear growth engine, delivering 11% organic sales growth alongside 100-bp adjusted EBITDA margin expansion to 26.6%. This strength was fueled by AI-driven demand for data center power solutions, semiconductor applications, and space & defense markets. Despite gross margin compression of 40 bps, adjusted EBITDA margin expanded 50 bps to 26%, suggesting the company's 80/20 initiatives are gaining traction.Overall, Q1 results were encouraging and contributed to our raised growth outlook for the year.
$IEX
Research
Research Alert: CFRA Reiterates Hold Opinion On Shares Of Iex
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We lift our 12-month target to $235 from $220 following Q1, valuing shares at 26x our 2027 EPS outlook of $9.04 (up from $8.99; 2026 EPS view revised to $8.50 from $8.28). IEX posted a robust Q1, with operating EPS of $2.00 rising 14% Y/Y and exceeding consensus by $0.23, propelled by standout performance in Health & Science Tech. Organic sales growth accelerated to 5% Y/Y from 1% in Q4, while orders hit a record $988M (up 10% Y/Y), signaling broadened demand. Health & Science Tech was the clear growth engine, delivering 11% organic sales growth alongside 100-bp adjusted EBITDA margin expansion to 26.6%. This strength was fueled by AI-driven demand for data center power solutions, semiconductor applications, and space & defense markets. Despite gross margin compression of 40 bps, adjusted EBITDA margin expanded 50 bps to 26%, suggesting the company's 80/20 initiatives are gaining traction.Overall, Q1 results were encouraging and contributed to our raised growth outlook for the year.
$IEX
Wire
Citigroup Adjusts Price Target on IDEX to $252 From $243
IDEX (IEX) has an average rating of overweight and mean price target of $236.46, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $218.37, Change: $+1.03, Percent Change: +0.47%
$IEX
Wire
Stifel Adjusts Price Target on IDEX to $250 From $241
IDEX (IEX) has an average rating of overweight and mean price target of $236.46, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $218.37, Change: $+1.03, Percent Change: +0.47%
$IEX
Wire
BMO Capital Adjusts Price Target on IDEX to $230 From $214
IDEX (IEX) has an average rating of overweight and mean price target of $236.46, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $218.48, Change: $+1.14, Percent Change: +0.52%
$IEX
Wire
Baird Adjusts Price Target on IDEX to $257 From $247
IDEX (IEX) has an average rating of overweight and mean price target of $236.46, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $218.35, Change: $+1.01, Percent Change: +0.46%
$IEX
Wire
Mizuho Adjusts Price Target on IDEX to $210 From $170
IDEX (IEX) has an average rating of overweight and mean price target of $236.46, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $218.35, Change: $+1.01, Percent Change: +0.46%
$IEX
Wire
BNP Paribas Adjusts Price Target on IDEX to $210 From $200
IDEX (IEX) has an average rating of overweight and mean price target of $236.46, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $218.35, Change: $+1.01, Percent Change: +0.46%
$IEX
Wire
Citigroup Adjusts Price Target on IDEX to $252 From $243
IDEX (IEX) has an average rating of overweight and mean price target of $236.46, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $218.56, Change: $+1.22, Percent Change: +0.56%
$IEX
Wire
Oppenheimer Adjusts Price Target on IDEX to $242 From $230, Maintains Outperform Rating
IDEX (IEX) has an average rating of overweight and mean price target of $236.46, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $219.82, Change: $+2.47, Percent Change: +1.14%
$IEX
Research
Research Alert: Idex: High-growth Market Exposure Fuels Q1 Beat
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:IEX's Q1 results significantly exceeded expectations with operating EPS of $2.00 (up 14% Y/Y) vs. consensus of $1.77, representing a solid $0.23 beat, while organic sales growth accelerated to 5% from Q4's 1%. Orders hit a record $988M (up 10%) as demand broadened across the diversified portfolio. The Health & Science Tech segment was the primary growth driver, with 17% reported and 11% organic sales growth, plus 100 bps of adjusted EBITDA margin expansion to 26.6%, underpinned by AI-driven data center power solutions demand and semiconductor applications. Management raised full-year 2026 guidance, projecting organic sales growth of 3%-4% (up from 1%-2%) and adjusted EPS of $8.35-$8.55 (up from $8.15-$8.35). While gross margin declined 40 bps to 44.9% due to unfavorable mix, adjusted EBITDA margin expanded 50 bps to 26%, as 80/20 initiatives bear fruit. In our view, the upgraded outlook reflects an improved demand backdrop across IEX's diversified end markets.
$IEX
